Cargando…
Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma
BRAF inhibitors revolutionised the management of melanoma patients and although resistance occurs, there is a subgroup of patients who maintain durable disease control. For those cases with durable complete response (CR) it is not clear whether it is safe to cease therapy. Here we identified 13 pati...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606504/ https://www.ncbi.nlm.nih.gov/pubmed/33139839 http://dx.doi.org/10.1038/s41598-020-75837-5 |